Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

"My Health Priorities" Program for Rural and Underserved Older Adults With Multiple Chronic Conditions (MyHP-South)

3 novembre 2026 aggiornato da: Deborah Ejem, University of Alabama at Birmingham

Refinement and Pilot Testing of the "My Health Priorities" Program for Rural and Underserved Older Adults With Multiple Chronic Conditions in the Deep South (MyHP-South)

The goal of this clinical trial is to evaluate the feasibility and acceptability of the revised My Health Priorities (MyHP) program among rural and underserved older adults with multiple chronic conditions in the Deep South. The program is designed to help participants clarify their health-related values, as well as improve communication with family caregivers and healthcare providers to support medical decision-making. The main question this study aims to answer is whether the revised MyHP program is practical/easy for individuals to use, and if it helps support necessary conversations about healthcare priorities. Participants will be asked to complete the revised MyHP program over a Zoom or in-person session with their caregiver, as well as complete questionnaires over a telephone interview before and 12 weeks after the completion of the program. In addition to participating in the MyHP program, caregivers will also be asked to complete a series of questionnaires over a telephone interview before and 12 weeks after the program. Both patients and caregivers will also be asked to complete a brief survey about their experience with the program over a telephone interview.

Panoramica dello studio

Stato

Non ancora reclutamento

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

44

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Alexis M Johnson, B.S.
  • Numero di telefono: 205-975-1864
  • Email: amjohns2@uab.edu

Backup dei contatti dello studio

  • Nome: Deborah B Ejem, Ph.D.
  • Numero di telefono: 205-996-1671
  • Email: tejem@uab.edu

Luoghi di studio

    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35233
        • The Whitaker Clinic of the University of Alabama at Birmingham (UAB) Hospital
        • Contatto:
          • Alexis M Johnson, B.S.
          • Numero di telefono: 205-975-1864
          • Email: amjohns2@uab.edu
        • Contatto:
          • Deborah B Ejem, Ph.D.
          • Numero di telefono: 205-996-1671
          • Email: tejem@uab.edu

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria for Patients:

  1. Identifies as African American or White/Caucasian
  2. Is 65 years of age or older
  3. Has at least two of the following chronic conditions: cancer, heart disease, kidney disease, liver disease, or lung disease
  4. English-speaking and able to complete baseline study measures
  5. Cognitively able to participate in decision-making discussions
  6. Has a family caregiver that meets the eligibility requirements
  7. Has reliable telephone access

Inclusion Criteria for Caregivers:

  1. Identifies as African American or White/Caucasian
  2. Is 18 years of age or older
  3. A relative, partner, or friend who provides unpaid assistance or support with health-related decision-making (may or may not live in the same residence)
  4. English-speaking and able to complete baseline study measures
  5. Cognitively able to participate in decision-making discussions
  6. Has reliable telephone access

Exclusion Criteria for Patients:

  1. Has a documented diagnosis of dementia
  2. Is unable to understand the study and provide informed consent
  3. Resides in a nursing home or assisted living facility

Exclusion Criteria for Caregivers:

  1. Is unable to understand the study and provide informed consent
  2. Is unable to communicate with research staff
  3. Is unable to participate in the dyadic MyHP-South session and required assessments

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: MyHP-South Users

Includes the patients and caregivers who will be utilizing the MyHP-South program, as well as evaluating its feasibility/accessibility based on clarity, cultural relevance, usability, content, and delivery. This arm also includes the clinicians who will be assessing the usefulness of the program in a primary care setting.

Participants will use the refined My Health Priorities South (MyHP-South) program to help identify and communicate personal health priorities, then evaluate its feasibility/accessibility based on clarity, cultural relevance, usability, content, and delivery.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Patient System Usability Scale (SUS)
Lasso di tempo: At the MyHP-South session, within 14 days after baseline.

Over a Zoom or telephone interview, patients will answer ten questions regarding the accessibility/usability of the revised MyHP-South tool. Answer options will follow a ranked, Likert-type frequency scale, with answers ranging from 1: strongly disagree, to 5: strongly agree.

At the MyHP-South session, within 14 days after baseline.
Acceptability Interview
Lasso di tempo: At the MyHP-South session, within 14 days after baseline.

Over a Zoom or telephone interview, both patients and caregivers will together answer 26 questions regarding their experience using the revised MyHP-South tool. Answer options will be open-ended.

At the MyHP-South session, within 14 days after baseline.
Recruitment Feasibility
Lasso di tempo: From initiation of recruitment through enrollment of the final dyad (approximately 12 months).

Indicated by the number and proportion of eligible patient-caregiver dyads who enroll.

From initiation of recruitment through enrollment of the final dyad (approximately 12 months).
Retention and Completion Feasibility
Lasso di tempo: From baseline through 12 weeks after the MyHP-South session.

Indicated by the number and proportion of enrolled dyads completing baseline assessments, the MyHP-South session, immediate post-session assessments, the acceptability interview, and the 12-week assessments.

From baseline through 12 weeks after the MyHP-South session.
Caregiver System Usability Scale (SUS)
Lasso di tempo: Immediately after the MyHP-South session, during the same study visit.

Over a Zoom or telephone interview, caregivers will answer ten questions regarding the accessibility/usability of the revised MyHP-South tool. Answer options will follow a ranked, Likert-type frequency scale, with answers ranging from 1: strongly disagree, to 5: strongly agree.

Immediately after the MyHP-South session, during the same study visit.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
CollaboRATE Scale Score
Lasso di tempo: At baseline and 12 weeks after the MyHP-South session.

Over a telephone interview, patients will answer three questions regarding their experience with their healthcare provider during a clinical encounter. Answer options will follow a ranked scale ranging from zero to nine and will then be calculated into a final score/percentage.

At baseline and 12 weeks after the MyHP-South session.
Treatment Burden Questionnaire (TBQ) Score
Lasso di tempo: At baseline and 12 weeks after the MyHP-South session.

Over a telephone interview, patients will answer 13 questions regarding the potential burden of managing multiple chronic conditions. Answer options will follow a ranked scale ranging from zero to ten and will then be calculated into a final score.

At baseline and 12 weeks after the MyHP-South session.
Patient Shared Care Instrument Score
Lasso di tempo: At baseline and 12 weeks after the MyHP-South session.

Over a telephone interview, patients will answer 19 questions regarding communication, decision making, and reciprocity with their caregiver. Answer options will follow a Likert-type frequency scale, which will be calculated into final scores for each of the three subscales.

At baseline and 12 weeks after the MyHP-South session.
Bakas Caregiver Outcomes Scale (BCOS)
Lasso di tempo: At baseline and 12 weeks after the MyHP-South session.

Over a telephone interview, caregivers will answer 10 questions regarding potential life changes that have occurred as a result of serving as a caregiver. Answer options will follow a ranked, Likert-type frequency scale, with answers ranging from -3: changed for the worse, to +3: changed for the best.

At baseline and 12 weeks after the MyHP-South session.
Older Patient Assessment of Chronic Illness Care (O-PACIC) Scale Score
Lasso di tempo: At baseline and 12 weeks after the MyHP-South session.

Over a telephone interview, patients will answer ten questions regarding the quality of medical care they have received over the past six months. Answer options will follow a Likert-type frequency scale, which will then be calculated into a final score.

At baseline and 12 weeks after the MyHP-South session.
Caregiver Shared Care Instrument Score
Lasso di tempo: At baseline and 12 weeks after the MyHP-South session.

Over a telephone interview, caregivers will answer 19 questions regarding communication, decision making, and reciprocity with their patient. Answer options will follow a Likert-type frequency scale, which will be calculated into final scores for each of the three subscales.

At baseline and 12 weeks after the MyHP-South session.

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Timing Log for MyHP-South Session
Lasso di tempo: At the MyHP-South session, within 14 days after baseline.

Research staff will document the length of each MyHP-South session by documenting what time the session started and what time the session ended. Time used to navigate technical difficulties will be subtracted. Tracking how long the session takes serves as a measure of feasibility.

At the MyHP-South session, within 14 days after baseline.
Clinician Feedback Survey
Lasso di tempo: Within 6 months after the completion of the MyHP-South session.

Over an electronic survey, clinicians who provide care to enrolled patients will answer ten questions regarding the clarity, fit, and usefulness of the revised MyHP-South in a primary care setting.

Within 6 months after the completion of the MyHP-South session.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Deborah B Ejem, Ph.D., University of Alabama at Birmingham

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 gennaio 2027

Completamento primario (Stimato)

31 dicembre 2027

Completamento dello studio (Stimato)

31 dicembre 2027

Date di iscrizione allo studio

Primo inviato

29 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

3 novembre 2026

Primo Inserito (Effettivo)

9 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • IRB-300016725
  • U54AG093230 (Sovvenzione/contratto NIH degli Stati Uniti)
  • 606877 (Altro identificatore: ASSIST Study ID)
  • DGCG-11797 (Altro identificatore: NIA CROMS Study ID)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi